Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy.
Immunotherapy. 2020 Apr;12(6):417-429. doi: 10.2217/imt-2019-0190. Epub 2020 Apr 19.
A better understanding of the molecular pathogenesis of cutaneous immune disorders, together with advances in pharmaceutical drug development, led to the introduction of small-molecule inhibitors in the therapeutic management of a large spectrum of skin immune conditions. Small molecules are agents with a low molecular weight that are capable of affecting proinflammatory pathways through modulation of intracellular targets. These agents promise to improve the therapeutic management of many skin immune disorders due to their easy administration, high bioavailability and favorable safety profile. Here, we review the major small-molecule inhibitors targeting receptor-associated kinases, second messengers and transcription factors in development for the treatment of cutaneous immune conditions.
更好地理解皮肤免疫紊乱的分子发病机制，加上药物开发方面的进展，使得小分子抑制剂在治疗多种皮肤免疫疾病方面得以应用。小分子是指分子量较低的药物，能够通过调节细胞内靶点来影响促炎途径。这些药物具有易于给药、高生物利用度和良好的安全性等特点，有望改善许多皮肤免疫疾病的治疗管理。在这里，我们综述了用于治疗皮肤免疫疾病的靶向受体相关激酶、第二信使和转录因子的主要小分子抑制剂。
